- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05459298
ViDES Trial (Vitamin D Extra Supplementation)
July 13, 2023 updated by: Maria del Mar Romero López, The University of Texas Health Science Center, Houston
Randomized Trial of Enteral Vitamin D Supplementation in Infants < 28 Weeks Gestational Age or <1000 Grams Birth Weight
The objective of the study is to compare supplementation with vitamin D at 800 IU/day to usual care for the first 28 days after birth with respect to 25 (OH) vitamin D levels and indicators of likely or plausible effects of vitamin D supplementation on the function or structure of the lung, bones, immune system, and brain in extremely premature (EP) infants who are <28 weeks gestational age (GA) or <1000 grams of birth weight (BW).
The study results will be analyzed as intention to treat Bayesian analyses (Frequentist analyses will also be performed).
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
180
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maria del Mar Romero López, MD
- Phone Number: 713-500-7283
- Email: Maria.del.Mar.RomeroLopez@uth.tmc.edu
Study Contact Backup
- Name: Emily K Stephens, BSN, RNC-NIC
- Phone Number: (713) 500-5734
- Email: Emily.K.Stephens@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77006
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Maria del Mar Romero López, MD
- Phone Number: 713-500-7283
- Email: Maria.del.Mar.RomeroLopez@uth.tmc.edu
-
Contact:
- Emily Stephens, BSN, RNC-NIC
- Phone Number: (713) 500-5734
- Email: Emily.K.Stephens@uth.tmc.edu
-
Sub-Investigator:
- Matthew Rysavy, MD, PhD
-
Sub-Investigator:
- Amir Khan, MD
-
Sub-Investigator:
- Jon Tyson, MD, MPH
-
Sub-Investigator:
- Claudia Pedroza, PhD
-
Sub-Investigator:
- Mamta Naik, RD, PharmD, BCPPS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 4 days (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Infants born at < 28 weeks gestational age (GA) or <1000 grams birth weight (BW)
- Inborn
- Informed written consent in an Institutional Review Board (IRB)-approved manner
Exclusion Criteria:
- GA >32 weeks regardless of birth weight (BW)
- Any major congenital anomaly
- A known congenital nonbacterial infection
- Prenatal diagnosis of disorders that affect vitamin D absorption (e.g, cystic fibrosis)
- Such severe illness or immaturity that the attending neonatologist judges intensive care to be unjustified.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Usual care plus placebo
Infants will receive placebo (normal saline) in the first 28 days after birth.
Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices.
When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
|
Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
Other Names:
Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices.
When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
|
Experimental: Usual care plus vitamin D supplementation
Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day (when feedings reach about 120 -160 mL/kg/day).
At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
|
Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices.
When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day).
At that point the intervention becomes a supplement of 400 IU/day above that given with usual care.
In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
25-hydroxyvitamin D (25[OH]D) level
Time Frame: about 28 days after birth
|
about 28 days after birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
25-hydroxyvitamin D (25[OH]D) level
Time Frame: 36 weeks after birth
|
36 weeks after birth
|
|
Type of respiratory support required at 36 weeks postmenstrual age
Time Frame: 36 weeks postmenstrual age (or at the time of discharge home if earlier)
|
Data will be reported categorically as:
|
36 weeks postmenstrual age (or at the time of discharge home if earlier)
|
Length of Hospital stay
Time Frame: from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
|
Number of participants who are still on respiratory support
Time Frame: 22 to 26 months corrected age
|
Respiratory support includes supplemental oxygen and positive pressure ventilation.
|
22 to 26 months corrected age
|
Number of days of supplemental oxygen
Time Frame: from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
|
Number of days of mechanical ventilation
Time Frame: from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
|
Number of days of positive pressure support
Time Frame: from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
from time of birth to time of discharge (about 0 to 60 weeks after birth)
|
|
Number of participants who receive steroid treatment to decrease respiratory support
Time Frame: from baseline to 36 weeks postmenstrual age
|
from baseline to 36 weeks postmenstrual age
|
|
Number of participants with pulmonary hypertension
Time Frame: 36 weeks postmenstrual age
|
36 weeks postmenstrual age
|
|
Number of participants with wheezing
Time Frame: 2 years
|
2 years
|
|
Weight as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 28 days of life
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
28 days of life
|
Weight as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 36 weeks postmenstrual age
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
36 weeks postmenstrual age
|
Weight as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 2 years
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
2 years
|
Length as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 28 days of life
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
28 days of life
|
Length as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 36 weeks postmenstrual age
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
36 weeks postmenstrual age
|
Length as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 2 years
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
2 years
|
Head circumference as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 28 days of life
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
28 days of life
|
Head circumference as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 36 weeks postmenstrual age
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
36 weeks postmenstrual age
|
Head circumference as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Time Frame: 2 years
|
Z-scores range from -4 standard deviations to +4 standard deviations.
A higher Z-score indicates a better outcome.
|
2 years
|
Number of participants with any fractures
Time Frame: from baseline to 36 weeks postmenstrual age
|
from baseline to 36 weeks postmenstrual age
|
|
Number of participants with hospital-acquired sepsis
Time Frame: from day 3 after birth to the time of discharge (which is 0 to 60 weeks after birth)
|
from day 3 after birth to the time of discharge (which is 0 to 60 weeks after birth)
|
|
Calcium level
Time Frame: 0 to 36 weeks postmenstrual age
|
0 to 36 weeks postmenstrual age
|
|
Phosphorus level
Time Frame: 0 to 36 weeks postmenstrual age
|
0 to 36 weeks postmenstrual age
|
|
Alkaline phosphatase level
Time Frame: 0 to 36 weeks postmenstrual age
|
0 to 36 weeks postmenstrual age
|
|
Neurodevelopment as assessed by the Bayley-IV Scales of Infant and Toddler Development
Time Frame: 2 years
|
Score ranges from 40 to 160, with a higher score indicating a better outcome.
|
2 years
|
Number of participants with neurodevelopmental impairment (NDI)
Time Frame: 2 years
|
2 years
|
|
Number of participants who die or have a morbidity
Time Frame: 36 weeks postmenstrual age
|
Morbidities include retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), neurodevelopmental impairment (NDI), necrotizing enterocolitis (NEC), and patent ductus arteriosus (PDA).
|
36 weeks postmenstrual age
|
Vitamin D status as indicated by serum concentration of 24,25(OH)2D3 as assessed by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS)
Time Frame: about 28 days after birth
|
about 28 days after birth
|
|
Vitamin D status as indicated by serum concentration of 24,25(OH)2D3 as assessed by LC-MS/MS
Time Frame: 36 weeks postmenstrual age
|
36 weeks postmenstrual age
|
|
Vitamin D status as indicated by serum concentration of 3-epi-25(OH)D3 as assessed by LC-MS/MS
Time Frame: about 28 days after birth
|
about 28 days after birth
|
|
Vitamin D status as indicated by serum concentration of 3-epi-25(OH)D3 as assessed by LC-MS/MS
Time Frame: 36 weeks postmenstrual age
|
36 weeks postmenstrual age
|
|
Vitamin D status as indicated by serum concentration of 25(OH)D3 as assessed by LC-MS/MS
Time Frame: about 28 days after birth
|
about 28 days after birth
|
|
Vitamin D status as indicated by serum concentration of 25(OH)D3 as assessed by LC-MS/MS
Time Frame: 36 weeks postmenstrual age
|
36 weeks postmenstrual age
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Maria del Mar Romero López, MD, The University of Texas Health Science Center, Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 6, 2022
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
July 11, 2022
First Submitted That Met QC Criteria
July 11, 2022
First Posted (Actual)
July 14, 2022
Study Record Updates
Last Update Posted (Actual)
July 17, 2023
Last Update Submitted That Met QC Criteria
July 13, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-22-0563
- KL2TR003168 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
University Hospital, Clermont-FerrandTerminated
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Okan UniversityArçelik A.Ş.Completed
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingVitamin d DeficiencyChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States